MOVING LIFE SCIENCE INNOVATIONS

FROM DISCOVERY TO DEVELOPMENT TO DELIVERY

OUR VISION OF THE FUTURE: Arizona is a top-ten life science state.

OUR MISSION: AZBio supports the needs of Arizona’s growing life science ecosystem.

OUR MEMBERS: AZBio Members make an impact. They discover, develop and deliver health innovations including medicines, medical devices, diagnostics, and a wide range of health technologies. Our members also include economic development partners, educators, investors, leading business and philanthropic organizations, and patient advocacy organizations. AZBio Members employ over 365,000 Arizonans who are working together to make life better for people in Arizona and around the world.

Our industry sector generated over $43.64 billion in Economic Impact in 2023.

That's up over 88% from 2016 and growing at a Compound Annual Growth Rate of 9.5%.

Arizona’s bioscience industry (not including our hospitals) employed 40,399 in 2023 across 3,652 state business establishments, representing a rapid 24.6 percent increase in employment since 2019 and placing the state among the leaders in employment growth. The average wage in the bioscience industry was $102,161—53 percent higher than the state’s private sector average. View More of Arizona's Bioscience Industry Data

A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on growing Arizona’s bioscience industry.

AZBio Member Organizations in the fields of business, research and education, health care delivery, economic development, government, and other professions involved in the biosciences are the key drivers of the growth of Arizona's life science sector. As the unified voice of our industry in Arizona, AZBio strives to make Arizona a place where bioscience organizations can grow and succeed.

AZBio works nationally and globally with the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Medical Device Manufacturers Association (MDMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and leading patient advocacy organizations.

Through these relationships, AZBio has access to information, contacts, resources, cost saving programs, and the global bioscience and medtech community.

Picard Medical Marks Public Company Milestone by Ringing the NYSE Opening Bell

Picard Medical, Inc. / SynCardia Systems LLC commemorate the Company’s transition to the public markets and continued advancement of their Total Artificial Heart technology

Phoenix Children’s Research Institute Secures Three Prestigious National Institutes of Health (NIH) Grants

Phoenix Children’s Research Institute at the University of Arizona College of Medicine – Phoenix has been awarded three new R01 grants from the National Institutes of Health (NIH), the gold standard of federally funded research awards.Grant funding will advance pediatric lung and spine research.

Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy to Newborn Screenings

WASHINGTON—DECEMBER 16, 2025 — The U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. today approved the addition of Duchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD) to the Recommended Uniform Screening Panel (RUSP) following scientific review and public comment. Early detection of both conditions allows children to receive FDA-approved therapies […]

NuvOx Announces First Patient in Phase IIb Stroke Trial

Tucson, AZ –December 15, 2025, NuvOx Therapeutics, Inc. (“NuvOx”) announced that the first patient has been enrolled in the Phase IIb NOVEL trial (NanO2 in Large Vessel Occlusion Stroke (NOVEL): a multicenter single-blind, randomized, placebo-controlled biomarker end point clinical trial of perfluorocarbon in acute ischemic stroke due to large vessel occlusion (LVO). The NOVEL trial […]